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Abstract JARID1B, a histone demethylase, has been report-
ed to be highly expressed in various human cancers. In the
present study, we investigated the association of JARID1B
level with epithelial ovarian cancer (EOC) and prognosis of
patients with EOC. We analyzed JARID1B expression in 20
normal ovaries, 20 benign ovarian tumor (BOT) samples, and
45 epithelial ovarian carcinoma specimens by quantitative
PCR (qRT-PCR) and western blotting analyses. JARID1B
was further examined in 120 EOC specimens from patients
with different histological stages via immunohistochemistry.
Possible correlations between JARID1B levels and prognosis
as well as chemotherapy resistance of EOC patients were
determined by univariate and multivariate analyses. JARID1B
level was significantly increased in EOC, as compared to
normal ovaries and BOT. Among 120 EOC cases examined,
the 5-year progression-free survival (PFS) rates were 17 and
85 % in patients with high and low JARID1B expression,
respectively (hazard ratio=17.85, 95 % confidence interval
(CI) 6.31–50.51, P<0.001). Similarly, the 5-year overall sur-
vival (OS) rates for patients with high and low JARID1B
expression were 28 and 92 % respectively (hazard ratio=
21.8, 95 % CI 5.92–71.81, P<0.001). Positive correlation
between JARID1B level and chemotherapy resistance was
observed in patients with EOC (odds ratio (OR) 36.81, 95 %
CI 4.84–280.11, P<0.001). JARID1B could serve as an im-
portant biomarker for prognosis and chemotherapy resistance
of EOC patients.
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Introduction
Ovarian carcinoma accounts for high lethality in women
malignancies worldwide [1]. Of all ovarian cancers, stages I
to IV are 7.2, 8.7, 72, and 12.1 % respectively [2]. Due to
lacking of effective tools for early detection, most patients
with EOC present with advanced stages at diagnosis. The
prognosis of EOC is usually poor with a 5-year survival rate
around 46 % [3]. Although sophisticated surgery and new
chemotherapy regimens appear in the recent years, the 5-
year survival rate for patients with EOC was not improved
significantly in the last two decades [4]. Failure of EOC
treatment is largely due to chemotherapy resistance, an impor-
tant prognostic index for EOC patients in clinical [3]. There-
fore, it is necessary to identify certain effective biomarker that
can help to predict the prognosis and chemotherapy resistance
of patients with EOC.
JARID1B, also known as PLU1 or KDM5B, is a histone
demethylase that converts tri- and di-methylated lysine 4 in
histone H3 (H3K4me3/2) to the mono-methylated form
(H3K4me1) [5–7]. JARID1B is highly expressed in human
cancers of the prostate, lung, and bladder as well as many
cancer cell lines [8, 9]. More recently, JARID1B came into the
spotlight for its association with a slow-cycling cell popula-
tion and drug resistance in melanoma [10, 11]. However, the
impact of JARID1B expression on the prognosis and chemo-
therapy resistance of patients with EOC has not been reported
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yet. Thus, the purpose of this study was to determine whether
JARID1B expression level is associated with the prognosis
and chemotherapy resistance of EOC and in turn improves the




A total of 120 cases of EOC patients were selected for
our study following the approval of the Institutional
Review Board, The Fourth Hospital of Harbin Medical
University. The criteria for selection include the follow-
ing: (1) confirmed diagnosis of EOC by pathological
examination, (2) complete clinical records, (3) no seri-
ous complications or other malignant diseases, (4) ab-
sence of prior treatment for cancer, and (5) already had
cytoreductive surgery. All selected patients were in-
formed about the illness and consent with the treatment
The selected patients received six courses of intravenous
platinum-based combination chemotherapy with 3 weeks be-
tween each course. The patients were divided into two groups
according to chemotherapy regimens received: (1) TP group
(53 patients): paclitaxel (175 mg/m2, 1 day) and cisplatin
(50 mg/m2, 2 days); (2) PAC group (60 patients): cisplatin
(70 mg/m2), cyclophosphamide (70 mg/m2), and epirubicin
(50 mg/m2).
Quantitative PCR (qRT-PCR)
Total RNA was extracted from human tissues using the
RNeasy Plus Mini Kit (74134, QIAGEN) and then converted
into cDNAs using the High Capacity cDNA Reverse Tran-
scription Kit (4368814, Applied Biosystems) following man-
ufacturer’s instruction. Quantitative PCR was performed with
a CFX96 (Bio-Rad) using the RT2 SYBR Green (330500, SA
Biosciences). The primer sequences for JARID1B were as
follows: 5′-AGAGGCTGAATG AG CTGGAG-3′ (forward)
and 5′-TGGCAATTTTGGTCCATTTT-3′ (reverse). All
values were normalized with glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) abundance. Data were presented as
the average of triplicates±SD.
Western blotting analysis
Frozen samples of EOC (45 cases), BOT (20 cases), and
normal ovary (20 cases) were homogenized in lysis buffer
consisting of 1 % Triton X-100 in phosphate-buffered
saline (PBS) supplemented with protease inhibitor cocktail
(Roche) and then incubated on ice for 30 min. After that,
the mixture was centrifuged at 12,000g for 15 min at 4 °C
and the supernatant collected. Sixty micrograms of protein
extracts were loaded onto 10 % SDS polyacrylamide gel
electrophoresis and transferred onto a PVDF membrane
(Millipore Company, USA). The blots were blocked with
blocking buffer (pH 7.6) containing 5 % nonfat dry milk
for 1 h and then incubated with rabbit polyclonal








<50 13 30 43
≥50 22 55 77
Serum CA-125 level 0.43
<35 4 6 10
≥35 31 79 110
Ascites 0.9
<100 6 13 19
≥100 29 72 101
Lymph node metastasis 0.0009
Absent 31 49 80




G1 13 11 24
G2 14 26 40
G3 8 48 56
Histology type 0.51
Serous adenocarcinoma 27 59 86




Clear cell carcinoma 0 2 2
Residual tumor size 0.11
<1 cm 30 56 86
1–2 cm 4 18 22
≥2 cm 1 11 12
FIGO stage 0.01
I and II 5 3 8
III and IV 30 82 112
Chemotherapy regimen 0.025
TP 22 34 56
PAC 10 52 64
Chemotherapy resistance <0.0001
Absent 32 56 88
Present 0 30 30
TP cisplatin and paclitaxel, PAC cisplatin, epirubicin, and
cyclophosphamide
a G1 is well differentiated, G2 moderately differentiated, and G3 poorly
differentiated
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antihuman JARID1B antibody (1:500) (HPA027179, Sig-
ma) overnight at 4 °C. Immunoreactive proteins were
stained using a chemiluminescence detection system.
Membranes were stripped with stripping buffer for 1 h
and re-probed with mouse actin that serves (Neomarkers,
Fremont, CA) as an internal control [2, 3].
Immunohistochemical staining
Paraffin-embedded patient samples of NO (22 cases), BOT
(28 cases), and EOC (120 cases) were sectioned onto slides at
a thickness of 4 μm. To stain JARID1B, the slides were first
deparaffinized in xylene and rehydrated with gradient concen-
trations of alcohol under standard procedures. After rehydra-
tion, the slides were immersed in 0.01 mol/l citrate buffer
(pH 6.0) and heated (95 °C) for 15 min for antigen retrieval.
Then, the samples were incubated with 3 % hydrogen perox-
ide (H2O2) for 10 min followed by 10 % normal goat serum
blocking for 10 min. Subsequently, the sections were incubat-
ed with primary rabbit polyclonal antihuman JARID1B anti-
body (dilution 1:100) (HPA027179, Sigma) for 1 h at room
temperature. After washing with PBS for 3 times, the sections
were incubated with biotin-labeled secondary antibody
followed by horseradish peroxidase (HRP)-conjugated
streptavidin for 30 min individually at room temperature.
After applying HRP substrate, 3.3′-diaminobenzidine tetrahy-
drochloride (Dako, Germany) in 0.01 % H2O2, for 10 min, the
slides were counterstained withMeyer’s hematoxylin for 30 to
60 s and mounted with mounting medium for visualization
under a microscope.
Semiquantitative analysis of JARID1B staining
Scoring of JARID1B in EOC samples via immunohis-
tochemistry (IHC) staining follows the methods previ-
ously published [2, 3]. All of IHC staining samples
from EOC patients were evaluated by two experienced
pathologists independently.
Fig. 1 a qRT-PCR assay of JARID1B levels in normal ovaries (NO),
benign ovarian tumor (BEOT), and ovarian carcinoma (EOC) tissues.
GAPDH serves as internal control. b The top panel presents the Western
blotting analysis of JARID1B expression in normal ovaries and in ovarian
carcinoma tissues. Protein samples obtained from frozen normal ovaries
(NO), benign ovarian tumor (BEOT), and ovarian carcinomas (EOC)
were analyzed by SDS-PAGE followed by immunoblotting with
antibody against JARID1B. The levels of GAPDH were used as an
internal control. The bottom panel presents the histogram of pooled
data from fresh normal ovaries (NO; n=20), benign ovarian tumor
(BEOT; n=20), and ovarian carcinomas (EOC; n=45). The expression
of JARID1B was increased both in ovarian carcinomas compared with
fresh normal ovaries. Each protein samples was repeated for three times
Fig. 2 Representative examples
show high and low JARID1B
expression (positivity+intensity)
in tissue samples. a The left panel
shows normal ovaries, score 0+0;
right panel shows benign ovarian
tumors, score 0+0. b The left
panel shows representative
staining patterns of low JARID1B
expression (well differentiation),
score 1+0. The medium panel
shows representative staining
patterns of high JARID1B
expression, score: 2+1; right
panel shows representative
staining patterns of super-high
JARID1B expression, score: 2+
2. (Original magnification, 200×)
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Chemotherapy resistance evaluation
All patients received cytoreductive surgery followed by
TP or PAC chemotherapy. Based on the interval from
the conclusion of chemotherapy to relapse, the patients
were divided into the chemotherapy-sensitive and
chemotherapy-resistant groups referring to the standards
previously reported [12].
Follow-up evaluation
During the follow-up period, EOC patients with post-
cytoreductive surgery and chemotherapy were requested to
perform serum CA-125 test, pelvic MRI, color Doppler ultra-
sound of the liver and kidney, and pulmonary X-rays every
3 months in the first 2 years, every 6 months from 3 to 5 years,
and annually thereafter. The end points of the study were
progression-free survival (PFS) and overall survival (OS) as
reported [12].
Statistical analysis
The differences of the demographic characteristics of
EOC patients were analyzed by the chi-square (χ2) or
Fisher’s exact test. The Kaplan-Meier method was used
to estimate PFS and OS while the difference in the
levels among possible prognostic factors was compared
by the log-rank test with univariate analyses. A multi-
variate Cox regression (proportional hazard model) was
employed to identify prognostic factors and evaluate the
independent impact of JARID1B level on PFS and OS.
The correlation between the level of JARID1B and
chemotherapy resistance was assessed by the odds ratio
(OR) and the 95 % confidence interval (CI) that were
estimated using univariate and multivariate logistic re-
gression with covariate adjustment. Statistical analyses
in this study were performed using SAS software (ver-
sion 9.1.4, SAS Institute, Cary, NC). All statistical tests
were two tailed, and P values less than 0.05 were
considered statistically significant.
Results
Demographic characteristics of EOC patients
The demographic and clinical pathological characteristics
of EOC patients are listed in Table 1. Of the 120 patients
with EOC, the percentage of the International Federation
of Gynecology and Obstetrics (FIGO) stages from I to IV
is 1.67, 4.17, 90.83, and 3.33 %, respectively. Moreover,
there were 110 cases with serum CA-125 level greater
than 35 (91.67 %) and 101 cases with ascites volume
more than 100 ml. The histopathological types of the
EOC included 86 (71.67 %) cases of serous, 14
(11.67 %) cases of mucinous, 18 (15 %) cases of
Fig. 3 Statistical analysis of JARID1B stain intensity in EOCwith FIGO
stages (I and II vs III and IV) (n=120, P=0.0001)
Fig. 4 Kaplan-Meier curves for
survival of prognosis in 120
patients with epithelial ovarian
carcinoma according to the
categories of low and high
expression of JARID1B
(analyzed with log-rank test). a
Progression-free survival. b
Overall survival
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endometrioid, and 2 cases (1 %) of clear cell carcinomas.
Lymph node metastasis was observed in 30 patients. Ad-
ditionally, the distribution range of histopathological dif-
ferentiation in 120 EOC patients from grades 1 to 3 is 25
(20.83 %), 39 (32.5 %), and 56 (46.67 %), respectively.
JARID1B expression is increased in EOC
In the present study, we detected that JARID1B mRNA level
was significantly increased in EOC as compared to normal
ovary (NO) and benign ovarian tumor (BOT) via qRT-PCR
(Fig. 1a). Consistently, the protein level of JARID1B was
significantly higher in EOC as compared to NO and BOT
(Fig. 1b).
Further analyses by immunohistochemical staining re-
vealed that JARID1B was hardly detectable in NO and BOT
(Fig. 2a), while strong staining of JARID1B was detected in
most EOC samples (Fig. 2b). Interestingly, we noticed that
among 120 cases of EOC, 11/24 (45.8 %) of G1, 26/40 (65%)
of G2, and 48/56 (85.7 %) of G3 tumors have a relatively high
Table 2 Univariate analysis of 120 patients with ovarian cancer
Variables OS P PFS P
Mean±SE 5-year (%) Mean±SE 5-year (%)
JARID1B expression <.001 <.001
Low 4.71±0.07 92 4.27±0.09 85
High 3.35±0.24 28 2.37±0.22 17
Residual tumor size 0.01 0.02
<1 cm 4.45±0.24 51 3.45±0.23 41
1–2 cm 3.37±0.38 35 2.30±0.33 25
≥2 cm 1.35±0.29 24 0.60±0.13 22
Serum CA-125 level 0.16 0.28
<35 3.24±0.37 71 2.07±0.17 57
≥35 4.07±0.22 44 3.12±0.21 36
Ascites 0.77 0.96
<100 2.49±0.27 50 2.45±0.37 37.5
≥100 4.15±0.23 45 3.19±0.22 37
Lymph node metastasis 0.02 0.003
Absent 3.67±0.21 54 2.86±0.19 48
Present 3.75±0.33 28 2.53±0.29 14
Histopathological differentiationa 0.12 0.035
G1 3.96±0.34 60 2.09±0.22 52
G2 3.82±0.29 50 3.13±0.25 44
G3 3.72±0.32 35 2.65±0.28 26
Histology type 0.12 0.36
Serous adenocarcinoma 4.35±0.24 48 3.34±0.23 39
Mucoid adenocarcinoma 3.90±0.49 50 2.01±0.31 41
Endometrioid adenocarcinoma 2.11±0.35 31 1.41±0.22 26
Clear cell carcinoma 2.02 100 1.66 100
Age (years) 0.93 0.91
<50 3.75±0.25 42 2.64±0.23 34
≥50 4.08±0.28 47 3.19±0.26 39
Chemotherapy regimen <.001 <.001
TP 5.33±0.26 73 4.29±0.26 61
PAC 2.76±0.20 21 2.08±0.21 16
FIGO stage 0.02 0.004
I and II 4.21478±0.21885 47.46 3.25888±0.20959 38.73
III and IV 2.28819±0.63153 – 1.08681±0.31846 –
OS overall survival time. PFS progression-free survival time, TP cisplatin and paclitaxel, PAC cisplatin, epirubicin, and cyclophosphamide
a G1 is well differentiated, G2 moderately differentiated, and G3 poorly differentiated
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level of JARID1B (Fig. 2b), suggesting JARID1B level may
negatively correlate to EOC histopathological differentiation.
Furthermore, a significant difference in lymph nodemetastasis
was observed between JARID1B high- (36/85) and low-
expression groups (4/35) (Table 1, P<0.0009). In addition,
JARID1B level was significantly higher in late stages (III and
IV) than in early stages (I and II) of EOC samples (Fig. 3).
The association of JARID1B with prognosis of EOC
The Kaplan-Meier curves of PFS and OS for EOC patients
with either high or low level of JARID1B were shown in
Fig. 4. The average PFS for patients with high expression of
JARID1B was 2.37 years, which was significantly lower than
that for those with low JARID1B (4.27 years, P<0.001)
(Table 2). Similarly, OS for EOC patients with high level of
JARID1Bwas also significantly lower than that for those with
low JARID1B expression (P<0.001), which were 4.71 and
3.35 years, respectively (Table 2).
Besides JARID1B, we noticed there were some other fac-
tors that also had significant impact on PFS and OS of EOC
patients in univariate analyses. They include residual tumor
size, histopathological differentiation, lymph nodemetastases,
FIGO stage, and chemotherapy regimen (Table 2).
To evaluate the independent impact of JARID1B on the
PFS and OS for EOC patients, a multivariate Cox regression
model adjusted with other statistically significant prognostic
factors described above was performed. As shown in Table 3,
EOC patients with high level of JARID1B has a significantly
shorter PFS and OS than those with relatively low level of
JARID1B (PFS: hazard ratio=17.9, P<0.001; OS: hazard
ratio=21.8, P<0.001).
Impact of JARID1B overexpression on chemotherapy
resistance in ovarian cancers
Among 118 EOC patients who underwent chemotherapy (ex-
clude 2 patients of stage I), 88 patients were chemotherapy
sensitive while the other 30 patients presented with chemo-
therapy resistance, in which 29 (96.67 %) patients expressed
high level of JARID1B (Table 4). In addition to JARID1B,
chemotherapy resistance was also significantly associated
with residual tumor size and chemotherapy regimen (P=
0.004 and P<0.001, respectively) (Table 4). However, no
significant difference was found between the chemotherapy-
sensitive and chemotherapy-resistant groups in other factors
such as age, serum CA-125 concentration, ascites, lymph
Table 3 Multivariate analysis
with covariates adjustment of 120
patients with ovarian cancer
OS overall survival time, PFS
progression-free survival time, TP
cisplatin and paclitaxel, PAC
cisplatin, epirubicin, and
cyclophosphamide
a Likelihood ratio test, P<.001
b Likelihood ratio test, P<.001
c G1 is well differentiated, G2
moderately differentiated, and
G3 poorly differentiated
Prognostic variables OSa PFSb
HR 95 % CI P value HR 95 % CI P value
JARID1B expression
Low
High 21.8 5.92,71.81 <.001 17.85 6.31,50.51 <.001
Lymph node metastasis
Absent
Present 0.772 0.44,1.35 0.36 0.93 0.55,1.59 0.81
Histopathological differentiationc
G3
G2 0.94 0.51,1.7 0.84 0.80 0.45,1.41 0.43
G1 1.55 0.69,3.46 0.28 2.27 1.06,4.88 0.04
Chemotherapy regimen
TP
PAC 5.14 2.77,9.5 <.001 4.53 2.58,7.96 <.001
Age (years)
<50
≥50 1.27 0.72,2.2 0.41 1.16 0.70,1.93 0.56
FIGO stage
I and II
III and IV 2.26 0.74,6.90 0.15 5.30 1.71,16.41 0.0038
Residual tumor size
<1 cm
1–2 cm 0.79 0.42,1.51 0.48 0.92 0.50,1.71 0.80
≥2 cm 4.078 1.7,9.80 <.001 3.31 1.41,7.74 <.001
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node metastases, histopathological differentiation, and histo-
pathological type.
To evaluate the independent impact of JARID1B on che-
motherapy resistance, a multivariate logistic regression model
adjusted with other statistically-significant factor including
residue tumor size and chemotherapy regimen was applied.
The results revealed that high level of JARID1B was inde-
pendently associated with chemotherapy resistance (OR
36.81, 95 % CI 4.84–280.11, P<0.001) (Table 5).
Discussion
To date, the associations between JARID1B level and prog-
nosis as well as chemotherapy resistance in EOC have not
been reported. This is the first study to investigate the impact
of JARID1B overexpression on prognosis and chemotherapy
resistance using a large number of clinical samples. In this
study, we analyzed JARID1B expression in 120 patients with
EOC by immunohistochemistry and found that JARID1Bwas
an independent factor for both prognosis and chemotherapy
resistance of EOC.
This study analyzed the association between JARID1B
expression and traditional clinicopathogical characteristics in
EOC. JARID1B expression was associated with lymph node
metastases, FIGO stages, and histopathological differentia-
tion, which could be helpful in understanding the progression
and prognosis of patients with EOC.
The present data demonstrated that JARID1B overexpression
was associated with poor survival by analyzing the OS and PFS.
In this study, amultivariate Cox regression analysis indicated that
JARID1B expression and histopathological differentiation were
independent prognostic factors for OS and PFS in EOC. The
results of this study are consistent with previously reported
results. Shoji et al. [13] found that high luminal JARID1B
activity is associatedwith poor outcome in patientswith hormone
receptor-positive breast tumors. Yoshihiro et al. [14] results
indicated that JARID1B plays a role in maintaining cancer stem
Table 4 Demographic characteristics of patients undergoing








<50 34 8 42
≥50 54 22 76
Serum CA-125 level 0.20
<35 8 1 9
≥35 80 29 109
Ascites 0.9
<100 13 5 18
≥100 75 25 100
JARID1B expression <0.001
Low 34 1 35
High 54 29 83
Lymph node metastasis 0.85
Absent 60 19 79
Present 28 11 39
Histopathological differentiationa 0.06
G1 19 4 23
G2 33 6 39
G3 36 20 56
Histology type 0.77
Serous adenocarcinoma 64 21 85




Clear cell carcinoma 1 0 1
Residual tumor size 0.004
<1 cm 70 16 86
1–2 cm 15 8 22
≥2 cm 3 7 10
Chemotherapy regimen <0.001
TP 50 5 55
PAC 38 27 63
FIGO stage 0.91
II 2 3 5
III 83 26 109
IV 3 1 4
TP cisplatin and paclitaxel, PAC cisplatin, epirubicin, and
cyclophosphamide
a G1 is well differentiated, G2 moderately differentiated, and G3 poorly
differentiated
Table 5 Multivariate analysis of the association between
chemotherapy resistance and JARID1B expression in epithelial ovarian
cancers
Variables bβ SE bβ
 




1–2 cm 0.95 0.58 3 0.12 3.1 (0.95,4.16)








High 3.60 1.04 11.91 <0.001 36.81
(4.84,280.11)
bβ and SE bβ
 
are the parameter estimator of association coefficient and
its standard error
χ2 chi-square statistic,OR odds ratio,CI confidence interval, TP cisplatin
and paclitaxel, PAC cisplatin, epirubicin, and cyclophosphamide
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cells in the esophagus and justifies the rationale for studying the
effects of continuous inhibition of this epigenetic factor in esoph-
ageal cancer. Zhang et al. [15] findings suggest that Myc-
mediated transcriptional repression of JARID1B counterintui-
tively inhibits Myc-regulated cell proliferation and potentially
tumorigenesis. Radberger et al. reported a statistically significant
association (P<0.05) between JARID1B expression and OS in
uveal melanoma [16]. We found similar association in EOC
patients. Among 120 EOC samples examined, JARID1B was
highly expressed in 85 cases (71%), suggesting JARID1Bmight
be an independent biomarker for EOC. It has been reported that
JARID1B might play an important role in the initiation and
development of prostate cancer [17]. In the present study, we
observed that JARID1B level was pretty low or nearly undetect-
able in normal ovary and benign ovarian tumor samples while it
was significantly increased in EOC, suggesting JARID1B might
also play an important role in tumorigenesis of EOC.
A common reason for poor prognosis of EOC results from
chemotherapy resistance. High expression of JARID1B has
been reported in a variety of cancers including prostate, mel-
anoma, and breast cancer [6, 11, 17]. Our study is the first to
describe the association between JARID1B and chemothera-
py resistance as well as prognosis for EOC. Specifically, we
found that high level of JARID1B is tightly associated with
chemotherapy resistance after adjusted with other factors that
correlate to chemotherapy resistance such as residual tumor
size and chemotherapy regimen via multivariate logistic re-
gression analysis (OR 36.81, 95 % CI 4.84–280.11,
P<0.001), indicating JARID1B is an independent factor for
chemotherapy resistance in EOC.
Our study also has some limitations. The sample size is
relatively small. Moreover, detailed mechanisms for
JARID1B affecting EOC chemotherapy resistance and prog-
nosis remain unclear and require further study.
In conclusion, JARID1B may serve as an important bio-
marker to predict chemotherapy resistance and prognosis for
EOC patients.
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